NASDAQ:ZFGN - Zafgen Stock Price, Forecast & News

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

Zafgen Inc (NASDAQ:ZFGN) posted its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.03. View Zafgen's Earnings History.

Zafgen is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Zafgen.

7 brokerages have issued twelve-month target prices for Zafgen's stock. Their forecasts range from $0.78 to $17.00. On average, they anticipate Zafgen's stock price to reach $7.06 in the next twelve months. This suggests a possible upside of 478.7% from the stock's current price. View Analyst Price Targets for Zafgen.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zafgen in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Zafgen.

Press coverage about ZFGN stock has trended somewhat positive on Monday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zafgen earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Zafgen.

Zafgen saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 520,800 shares, a decrease of 9.8% from the December 15th total of 577,500 shares. Based on an average trading volume of 687,800 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.6% of the shares of the company are short sold. View Zafgen's Current Options Chain.

Some companies that are related to Zafgen include Arcturus Therapeutics (ARCT), Harrow Health (HROW), Mustang Bio (MBIO), Aldeyra Therapeutics (ALDX), Obseva (OBSV), Galectin Therapeutics (GALT), Akorn (AKRX), Spero Therapeutics (SPRO), TAIWAN LIPOSOME/S (TLC), PhaseBio Pharmaceuticals (PHAS), Corvus Pharmaceuticals (CRVS), Agile Therapeutics (AGRX), Xeris Pharmaceuticals (XERS), CannTrust (CTST) and Adamas Pharmaceuticals (ADMS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include CA (CA), Endologix (ELGX), Energy Transfer LP Unit (ET), TG Therapeutics (TGTX), BlackRock (BLK), Fate Therapeutics (FATE), Gilead Sciences (GILD), Micron Technology (MU), SCYNEXIS (SCYX) and AT&T (T).

Zafgen's stock is owned by many different of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.23%). View Institutional Ownership Trends for Zafgen.

ZFGN stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Zafgen.

Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ZFGN stock can currently be purchased for approximately $1.22.

Zafgen has a market capitalization of $45.59 million. The biopharmaceutical company earns $-61,370,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. Zafgen employs 38 workers across the globe.View Additional Information About Zafgen.

The official website for Zafgen is http://www.zafgen.com/.

Zafgen's mailing address is 3 Center Plaza Suite 610, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]